Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

The median progression-free survival was 15.0 months in patients who received nivolumab plus rucaparib and 20.2 months in patients who received rucaparib alone. Adding nivolumab to rucaparib ...

Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast ...

Clovis CEO Patrick Mahaffy “The comprehensive ARIEL3 results presented for the first time today demonstrate the potential of rucaparib to extend the time during which the disease is controlled ...

There is a wide selection of therapies available for advanced prostate cancer treatment, but the optimal strategy for them is ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

The new indication would also extend Lynparza's lead in prostate cancer over rival PARP inhibitors like Clovis Oncology's Rubraca (rucaparib), GSK's Zejula (niraparib) and Pfizer's Talzenna ...

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

Patients with advanced pancreatic cancer with BRCA or PALB2 mutations who are sensitive to platinum-based chemotherapy may be candidates for maintenance therapy with rucaparib. News, April 02 ...